A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Inclusion Criteria:
Exclusion Criteria:
Clinical.Trials@bms.com855-907-3286
Dongguan Shi, Guangdong 523059, China
Weihui Shi, Henan 453100, China
Changsha Shi, Hunan 410013, China
Weifang Shi, Shandong 261000, China
Shanghai Shi, Shanghai Municipality 200120, China
Dazhou Shi, Sichuan 635000, China
Badsa, Haryana 124105, India
Toon-Shi, Ehime 791-0295, Japan
Kurume-Shi, Fukuoka 830-0011, Japan
Hirakata-Shi, Osaka 573-1191, Japan
Osakasayama-Shi, Osaka 589-8511, Japan
Buk-Gu, Daegu 41404, South Korea
Dalseo, Daegu 42601, South Korea
Hwasun-Gun, Jeollanam-do 58128, South Korea
Seocho -Gu, Seoul 6591, South Korea
Songpa-Gu, Seoul 138-736, South Korea
Gyeongsangnam-do, 050612, South Korea
Taipei City, Taipei 106, Taiwan